Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Temsirolimus
Drug ID BADD_D02151
Description Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
Indications and Usage For the treatment of renal cell carcinoma (RCC). Also investigated for use/treatment in breast cancer, lymphoma (unspecified), rheumatoid arthritis, and multiple myeloma.
Marketing Status Prescription
ATC Code L01EG01
DrugBank ID DB06287
KEGG ID D06068
MeSH ID C401859
PubChem ID 6918289
TTD Drug ID D0ES1Q
NDC Product Code 68254-6237; 0008-1179; 65219-200; 16729-223; 65727-047; 78848-002
Synonyms temsirolimus | rapamycin, 42-(3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate) | CCI 779 | CCI-779 | Torisel
Chemical Information
Molecular Formula C56H87NO16
CAS Registry Number 162635-04-3
SMILES CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O) C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypokalaemia14.05.03.002--
Hypophosphataemia14.04.03.001--
Immune system disorder10.02.01.001--Not Available
Impaired healing08.03.02.001--Not Available
Infection11.01.08.002--Not Available
Influenza22.07.02.001; 11.05.03.001--Not Available
Insomnia19.02.01.002; 17.15.03.002--
Interstitial lung disease10.02.01.033; 22.01.02.003--Not Available
Intestinal perforation07.04.06.002--Not Available
Lacrimation disorder06.08.02.010--Not Available
Laryngitis22.07.03.001; 11.01.13.001--
Leukopenia01.02.02.001--Not Available
Lung disorder22.02.07.001--Not Available
Lymphocyte count decreased13.01.06.006--
Lymphopenia01.02.02.002--Not Available
Mouth haemorrhage07.05.02.001; 24.07.02.014--
Mouth ulceration07.05.06.004--Not Available
Mucosal inflammation08.01.06.002--Not Available
Myalgia15.05.02.001--
Nail disorder23.02.05.002--
Nausea07.01.07.001--
Nervous system disorder17.02.10.001--Not Available
Neutropenia01.02.03.004--Not Available
Neutrophil count decreased13.01.06.010--
Oedema14.05.06.010; 08.01.07.006--Not Available
Oedema genital21.10.01.011--
Oedema peripheral14.05.06.011; 08.01.07.007; 02.05.04.007--
Ophthalmic herpes zoster06.04.05.023; 17.04.08.005; 11.05.02.021--Not Available
Oral pain07.05.03.002--
Pain08.01.08.004--
The 4th Page    First    Pre   4 5 6 7    Next   Last    Total 7 Pages